パラティン・テクノロジーズに関するコメント

The co-administration of bremelanotide with tirzepatide represents a novel therapeutic strategy for the treatment of obesity.
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...

Breakthrough in Dry Eye Disease Treatment: Insights from PL9643 MELODY-1 Phase 3 Trial.
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...